Search Within

Advanced Practice Providers

  1. "Hematologic Malignancies Research"
Formats
  1. Meeting Abstract (69)
  2. Journal Article (25)
  3. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (95)
  2. Department of Medicine (95)
  3. Hematologic Malignancies Research (95)
  4. Hematologic Malignancies, Division of (95)
  5. Nursing (80)
  6. GSK Faculty (79)

More Groups

People
  1. Renier Brentjens (52)
  2. Elizabeth Halton (48)
  3. Jae Park (46)
  4. Isabelle Riviere (38)
  5. Gunjan Shah (33)
  6. Maria Palomba (33)

More People

Years
  1. 2025 (1)
  2. 2024 (3)
  3. 2023 (5)
  4. 2022 (4)
  5. 2021 (9)
  6. 2020 (13)

More Years

Publications
  1. Blood (38)
  2. Journal of Clinical Oncology (16)
  3. Biology of Blood and Marrow Transplantation (7)
  4. Blood Advances (4)
  5. Hematological Oncology (3)
  6. Molecular Therapy (3)

More Publications

Publishers
  1. American Society of Hematology (42)
  2. American Society of Clinical Oncology (16)
  3. Elsevier Inc. (9)
  4. Nature Publishing Group (7)
  5. American Association for Cancer Research (5)
  6. Wiley Blackwell (4)

More Publishers

Results (95)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1
    Journal Article

    Naidoo, J.; Schindler, K.; Querfeld, C.; Busam, K.; Cunningham, J.; Page, D. B.; Postow, M. A.; Weinstein, A.; Lucas, A. S.; Ciccolini, K. T.; more...
    Cancer Immunology Research (2016)

    Fulltext@MSK | Save
  • Low dose unfractionated heparin (UFH) prophylaxis is a feasible strategy for the prevention of hepatic sinusoidal obstruction syndrome (SOS) after myeloablative adult allogeneic hematopoietic stem cell transplantation (HSCT)
    Meeting Abstract

    Bhatt, V.; Palazzo, M.; Kilroy, K.; Hilden, P.; Devlin, S. M.; Maloy, M.; Barker, J. N.; Castro-Malaspina, H.; Chung, D. J.; Dahi, P.; more...
    Biology of Blood and Marrow Transplantation (2016)

    Fulltext@MSK | Save
  • Low dose unfractionated heparin (UFH) prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome (SOS) in adult allogeneic stem cell transplant (HSCT) recipients
    Meeting Abstract

    Bhatt, V.; Palazzo, M.; Kilroy, K.; Hilden, P.; Maloy, M.; Barker, J. N.; Castro-Malaspina, H. R.; Chung, D. J.; Dahi, P. B.; Hsu, K. C.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Implications of minimal residual disease negative complete remission (MRD-CR) and allogeneic stem cell transplant on safety and clinical outcome of CD19 targeted 19-28z CAR modified T cells in adult patients with relapsed, refractory B-cell ALL
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X. Y.; Bernal, Y.; Purdon, T.; Halton, E.; Wang, Y.; Curran, K. J.; Sauter, C. S.; Sadelain, M.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Efficacy and safety of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed or refractory B-ALL
    Meeting Abstract

    Park, J.; Riviere, I.; Wang, X.; Bernal, Y.; Purdon, T.; Halton, E.; Curran, K.; Sauter, C.; Sadelain, M.; Brentjens, R.
    Haematologica (2015)

    Fulltext@MSK | Save
  • Phase I clinical trial of autologous CD19-targeted 19-28z CAR T cells in adult patients with Relapsed or refractory B-ALL
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X. Y.; Bernal, Y.; Halton, E.; Quintanilla, H.; Curran, K.; Sauter, C.; Sadelain, M.; Brentjens, R. J.
    Molecular Therapy (2015)

    Fulltext@MSK | Save
  • Efficacy and safety of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed or refractory B-ALL
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X. Y.; Bernal, Y.; Purdon, T.; Halton, E.; Curran, K. J.; Sauter, C. S.; Sadelain, M.; Brentjens, R. J.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)
    Meeting Abstract

    Sznol, M.; Kluger, H. M.; Callahan, M. K.; Postow, M. A.; Gordon, R. A.; Segal, N. H.; Rizvi, N. A.; Lesokhin, A. M.; Atkins, M. B.; Kirkwood, J. M.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • CD19-targeted 19-28z CAR modified autologous T cells induce high rates of complete remission and durable responses in adult patients with relapsed, refractory B-cell ALL
    Meeting Abstract

    Park, J. H.; Riviere, I.; Wang, X. Y.; Bernal, Y. J.; Yoo, S.; Purdon, T.; Halton, E.; Quintanilla, H.; Curran, K. J.; Sauter, C. S.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Survival, response duration, and activity by BRAF mutation (MT) status in a phase 1 trial of nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL)
    Meeting Abstract

    Kluger, H.; Sznol, M.; Callahan, M.; Postow, M.; Gordon, R.; Segal, N. H.; Rizvi, N.; Lesokhin, A.; Atkins, M. B.; Kirkwood, J.; more...
    Annals of Oncology (2014)

    Fulltext@MSK | Save